Moti Ramgopal

5.1k total citations
83 papers, 1.5k citations indexed

About

Moti Ramgopal is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Moti Ramgopal has authored 83 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Infectious Diseases, 37 papers in Virology and 23 papers in Emergency Medicine. Recurrent topics in Moti Ramgopal's work include HIV/AIDS drug development and treatment (55 papers), HIV Research and Treatment (37 papers) and HIV/AIDS Research and Interventions (31 papers). Moti Ramgopal is often cited by papers focused on HIV/AIDS drug development and treatment (55 papers), HIV Research and Treatment (37 papers) and HIV/AIDS Research and Interventions (31 papers). Moti Ramgopal collaborates with scholars based in United States, United Kingdom and Canada. Moti Ramgopal's co-authors include Rémi Fromentin, Nicolas Chomont, Claire Vandergeeten, Sandrina DaFonseca, Mariam B. Lawani, Jean‐Pierre Routy, Gordon Crofoot, Rafick‐Pierre Sékaly, Xuelian Wei and Irini Sereti and has published in prestigious journals such as Nature Medicine, Nature Communications and SHILAP Revista de lepidopterología.

In The Last Decade

Moti Ramgopal

73 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Moti Ramgopal United States	21	1.1k	901	418	322	250	83	1.5k
Silvia Nozza Italy	19	679 0.6×	724 0.8×	469 1.1×	284 0.9×	255 1.0×	148	1.3k
Benoît Trottier Canada	19	1.7k 1.5×	1.5k 1.7×	390 0.9×	374 1.2×	261 1.0×	68	2.2k
Maria Franca Pirillo Italy	19	933 0.8×	539 0.6×	378 0.9×	179 0.6×	127 0.5×	58	1.3k
Hans-Jürgen Stellbrink Germany	10	1.4k 1.2×	1.1k 1.2×	257 0.6×	584 1.8×	106 0.4×	12	1.7k
Alain Lafeuillade France	24	1.1k 1.0×	1.2k 1.3×	368 0.9×	280 0.9×	259 1.0×	89	1.7k
Michael Wohlfeiler United States	14	758 0.7×	637 0.7×	280 0.7×	209 0.6×	107 0.4×	31	1.1k
Lambert Assoumou France	21	858 0.8×	842 0.9×	240 0.6×	466 1.4×	255 1.0×	78	1.4k
Nicola Gianotti Italy	21	1.2k 1.1×	1.1k 1.2×	306 0.7×	305 0.9×	58 0.2×	153	1.5k
Josep M. Gatell Spain	22	991 0.9×	575 0.6×	780 1.9×	233 0.7×	227 0.9×	61	1.6k
Scott Hammer United States	14	1.3k 1.2×	1.1k 1.3×	280 0.7×	493 1.5×	78 0.3×	23	1.6k

Countries citing papers authored by Moti Ramgopal

Since Specialization

Citations

This map shows the geographic impact of Moti Ramgopal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Moti Ramgopal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Moti Ramgopal more than expected).

Fields of papers citing papers by Moti Ramgopal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Moti Ramgopal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Moti Ramgopal. The network helps show where Moti Ramgopal may publish in the future.

Co-authorship network of co-authors of Moti Ramgopal

This figure shows the co-authorship network connecting the top 25 collaborators of Moti Ramgopal. A scholar is included among the top collaborators of Moti Ramgopal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Moti Ramgopal. Moti Ramgopal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hagins, Debbie, Mezgebe Berhe, Gordon Crofoot, et al.. (2025). Final efficacy and safety of twice-yearly subcutaneous lenacapavir in treatment-naive people with HIV. AIDS. 40(3). 302–311.

Gathe, Joseph, Moti Ramgopal, Charlotte-Paige Rolle, et al.. (2025). Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled Trial. JAIDS Journal of Acquired Immune Deficiency Syndromes. 99(2). 185–194. 1 indexed citations

Dhippayom, Teerapon, Moti Ramgopal, Elizabeth M Sherman, et al.. (2025). Comparison of treatment‐emergent resistance‐associated mutations and discontinuation due to adverse events among integrase strand transfer inhibitor‐based single‐tablet regimens and cabotegravir + rilpivirine for the treatment of virologically suppressed people with HIV : A systematic literature review and network meta‐analysis. HIV Medicine. 26(8). 1184–1198. 1 indexed citations

Brar, Indira, Peter Ruane, Mezgebe Berhe, et al.. (2025). Efficacy and safety of switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir/abacavir/lamivudine: Results from an open-label extension of a phase 3 randomized, double-blind, multicenter, active-controlled, non-inferiority study. Medicine. 104(8). e41482–e41482.

Daar, Eric S., Chloe Orkin, Paul E. Sax, et al.. (2025). Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV. AIDS Research and Therapy. 22(1). 45–45.

Mounzer, Karam, Jihad Slim, Moti Ramgopal, et al.. (2024). Étude de phase 2 évaluant l'association BIC + LEN en prise orale quotidienne chez des personnes ayant un traitement du VIH par plusieurs comprimés. 3(2). S136–S136. 1 indexed citations

Riddler, Sharon A., Constance A. Benson, Steven G. Deeks, et al.. (2024). A Pooled Analysis of Eight Clinical Studies Suggests a Link Between Influenza-Like Symptoms and Pharmacodynamics of the Toll-Like Receptor-7 Agonist Vesatolimod. Infectious Diseases and Therapy. 13(11). 2285–2299. 1 indexed citations

Mounzer, Karam, Jihad Slim, Moti Ramgopal, et al.. (2024). Efficacy and Safety of Switching to Daily Bictegravir Plus Lenacapavir From a Complex HIV Treatment Regimen: A Randomized, Open-Label, Multicenter Phase 2 Study (ARTISTRY-1). Clinical Infectious Diseases. 80(4). 881–888. 3 indexed citations

Ogbuagu, Onyema, Jean‐Michel Molina, Ploenchan Chetchotisakd, et al.. (2024). Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multidrug-Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial. Clinical Infectious Diseases. 80(3). 566–574. 14 indexed citations

10.

Short, William R., et al.. (2023). 1985. A Prospective, Randomized Trial to Assess a Protease Inhibitor–based Regimen Switch Strategy to Manage Integrase Inhibitor–related Weight Gain. Open Forum Infectious Diseases. 10(Supplement_2). 5 indexed citations

11.

Ramgopal, Moti, et al.. (2023). Triple Threat: Triple Pathogen Endocarditis. Cureus. 15(10). e47860–e47860. 1 indexed citations

12.

Gupta, Samir K., Mezgebe Berhe, Gordon Crofoot, et al.. (2022). Lenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial. The Lancet HIV. 10(1). e15–e23. 65 indexed citations

13.

Fredericksen, Rob J., Heidi M. Crane, Jean Bacon, et al.. (2022). Utility and Impact of the Implementation of Same-Day, Self-administered Electronic Patient-Reported Outcomes Assessments in Routine HIV Care in two North American Clinics. AIDS and Behavior. 26(7). 2409–2424. 14 indexed citations

14.

Huhn, Gregory, Moti Ramgopal, Mamta K. Jain, et al.. (2020). HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens. PLoS ONE. 15(1). e0224875–e0224875. 5 indexed citations

15.

Wohl, David A., Yazdan Yazdanpanah, Axel Baumgarten, et al.. (2019). Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial. The Lancet HIV. 6(6). e355–e363. 116 indexed citations

16.

Ramgopal, Moti, et al.. (2016). Nocardia Bacteremia and Endocarditis in a Patient With a Sulfa Allergy. The American Journal of the Medical Sciences. 352(5). 542–543. 10 indexed citations

17.

Pozniak, Anton, José Ramón Arribas, Joseph Gathe, et al.. (2015). Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment. JAIDS Journal of Acquired Immune Deficiency Syndromes. 71(5). 530–537. 158 indexed citations

18.

Ramgopal, Moti, et al.. (2014). Origin of the dengue virus outbreak in Martin County, Florida, USA 2013. SHILAP Revista de lepidopterología. 1-2. 2–8. 26 indexed citations

19.

Ramgopal, Moti, et al.. (2013). Spinal osteomyelitis due toMycobacterium fortuitumin a former intravenous drug user. BMJ Case Reports. 2013. bcr2013010326–bcr2013010326. 9 indexed citations

20.

Ramgopal, Moti, et al.. (2013). Catastrophic antiphospholipid syndrome (CAPS) induced by influenza A virus subtype H1N1. BMJ Case Reports. 2013. bcr2013200474–bcr2013200474. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact